ExtraSuperTadarise is a combined preparation, whose main ingredients are Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE).

Precautions for Administration of ExtraSuperTadarise

Contraindications

Patients who are using any form of nitrate drugs (such as nitroglycerin, isosorbide mononitrate, etc.).

Patients with severe cardiovascular diseases or unstable angina pectoris.

Patients allergic to Tadalafil or Dapoxetine.

Patients with severe hepatic impairment.

Patients taking potent CYP3A4 inhibitors (such as ketoconazole, ritonavir, etc.) at the same time.

Administration in Special Populations

Patients with cardiovascular diseases: It is necessary to assess whether the heart condition is suitable for sexual activity.

Patients with hepatic impairment: Dosage adjustment is required for patients with mild to moderate hepatic impairment, while the drug is contraindicated for patients with severe hepatic impairment.

Patients with renal impairment: For patients with a creatinine clearance rate < 30 mL/min, the maximum dosage should not exceed 10 mg.

Elderly patients: Patients over 65 years old should use the drug with caution.

Dosage Regimen

The recommended dosage is once a day, taken orally as a whole tablet, and can be taken with food.

The drug works best when taken 30-60 minutes before sexual activity.

The dosage should not exceed once within 24 hours.

Avoid taking the drug with grapefruit juice.

Drug Interactions

Nitrate drugs: Concurrent use is absolutely contraindicated, as it may lead to life-threatening hypotension.

Alpha-blockers: May enhance the hypotensive effect.

CYP3A4 inhibitors: May increase the blood concentration of Tadalafil.

Antidepressants: May have interactions with Dapoxetine.

Medication Monitoring for ExtraSuperTadarise

Routine Monitoring Items

Cardiovascular function: Monitoring of blood pressure and heart rate.

Liver function: Regular examination of transaminases.

Renal function: Evaluation of creatinine clearance rate.

Visual function: Monitoring of color vision abnormalities.

Special Monitoring

Evaluation of sexual function improvement: Using the International Index of Erectile Function (IIEF) questionnaire.

Evaluation of premature ejaculation improvement: Recording the intravaginal ejaculatory latency time (IELT).

Evaluation of drug tolerance: Recording the occurrence of adverse reactions.

Self-Monitoring

Guide patients to identify and report the following situations in a timely manner:

Cases of priapism (abnormal and prolonged erection).

Symptoms of cardiovascular discomfort.

Changes in vision.

Mood swings.